Exhibit 99.1 | Varsity Tutors | | | | | | | CA19 3 Get help | | --- | --- | --- | --- | --- | --- | --- | --- | | B | · Nest-Generation Al-Pawered Learning Piatform | | | | | | | | Video | | | | | | | | | | Master any subject with | | | | | | | | Whiteboard | | | | | | | | | 3 | ractice | | | | | | | | Al tools | | | | | | | | | | subject. From math to science, history to languages - we've got you covered. | | | | | | | | Session checklist | Get personalized tutoring, proctice tests, and interactive tools t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-38848 STERIS plc (Exact name of registrant as specified in its charter) Ireland 98-145506 ...

Exhibit 99.1 10x Genomics Reports Third Quarter 2025 Financial Results PLEASANTON, Calif. November 6, 2025 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2025. Recent Updates "Our team delivered a solid third quarter, and we continue to see notable enthusiasm for our single cell and spatial products," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Our strong balance sheet and disciplined ex ...

Exhibit 99.1 Doximity Announces Fiscal 2026 Second Quarter Financial Results Total revenues of $168.5 million, up 23% year-over-year Operating cash flow of $93.9 million, up 37% year-over-year Free cash flow of $91.6 million, up 37% year-over-year SAN FRANCISCO, Calif., November 6, 2025 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 second quarter ended September 30, 2025. "Our platform continues to grow with new AI too ...

Teknova Reports Third Quarter 2025 Financial Results Third quarter 2025 total revenue was $10.5 million, up 9% from prior year Achieves five consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., November 6, 2025 – Alpha Teknova, Inc. ("Teknova" or the "Company") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Delaware 27-1488943 (State or other jurisdiction of incorporation or organization) Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35996 VivoSim Labs, Inc. (Exact name of registrant as ...

For the quarterly period ended September 30, 2025 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-41454 GIGACLOUD TECHNOLOGY INC (Exact Name of Registrant as Specified in its Charter) ____________ ...

Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026. Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related ...

Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026. Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic scler ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 28, 2025 BLOOMIN' BRANDS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Delaware 20 ...